Literature DB >> 1095489

Genetic instability of M protein and serum opacity factor of group A streptocci: evidence suggesting extrachromosomal control.

P P Cleary, Z Johnson, L Wannamaker.   

Abstract

The M antigen, a primary determinant of virulence in group A streptococci that is expressed biologically as resistance to phagocytosis, is known to undergo a variety of phenotypic changes both in vivo and in vitro. These changes are nonrandom and can occur at a high frequency. Using the previously described relationship between the serum opacity reaction (associated with certain strains) and the presence of the M antigen, the phenotypic instability of the M antigen was analyzed. The results support the conclusion that M protein synthesis and the serum opacity reaction are directly or indirectly controlled by the same gene or by genes which are linked and can segregate as a unit. Moreover, growth conditions and the curing agents rifampin and ethidium bromide had a discernible influence on the segregation of clones unable to exhibit serum opacity factor and to resist phagocytosis by human leukocytes. Serial transfer of stationary-phase cultures of four strains of group A streptococci significantly increased the number of colonies negative for the serum opacity reaction and the M antigen. For two of four strains both ethidium bromide and rifampin also increased the segregation of colonies with this phenotype. In light of these experiments and the necessary controls, the possible influence of plasmids or bacteriophage in regulating M protein synthesis is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1095489      PMCID: PMC415253          DOI: 10.1128/iai.12.1.109-118.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  ELIMINATION OF PENICILLIN RESISTANCE OF STAPHYLOCOCCUS AUREUS BY TREATMENT WITH ACRIFLAVINE.

Authors:  H HASHIMOTO; K KONO; S MITSUHASHI
Journal:  J Bacteriol       Date:  1964-07       Impact factor: 3.490

2.  SELECTION OF GROUP A STREPTOCOCCI RICH IN M-PROTEIN FROM POPULATIONS POOR IN M-PROTEIN.

Authors:  C G BECKER
Journal:  Am J Pathol       Date:  1964-01       Impact factor: 4.307

3.  Laboratory diagnosis of streptococcal infections.

Authors:  R E WILLIAMS
Journal:  Bull World Health Organ       Date:  1958       Impact factor: 9.408

4.  Studies of the carrier state following infection with group A streptococci. 1. Effect of climate.

Authors:  R M KRAUSE; C H RAMMELKAMP; F W DENNY; L W WANNAMAKER
Journal:  J Clin Invest       Date:  1962-03       Impact factor: 14.808

5.  Phase Variation in Salmonella.

Authors:  J Lederberg; T Iino
Journal:  Genetics       Date:  1956-09       Impact factor: 4.562

6.  Current knowledge of type-specific M antigens of group A streptococci.

Authors:  R C LANCEFIELD
Journal:  J Immunol       Date:  1962-09       Impact factor: 5.422

7.  Episome-mediated transfer of drug resistance in Enterobacteriaceae. V. Spontaneous segregation and recombination of resistance factors in Salmonella typhimurium.

Authors:  T WATANABE; K W LYANG
Journal:  J Bacteriol       Date:  1962-09       Impact factor: 3.490

8.  Factors affecting the chain length of group A streptococci. II. Quantative M-anti-M relationships in the long chain test.

Authors:  R D EKSTEDT; G H STOLLERMAN
Journal:  J Exp Med       Date:  1960-10-01       Impact factor: 14.307

9.  The occurrence of two M antigens in certain group A streptococci related to type 14.

Authors:  G G WILEY; A T WILSON
Journal:  J Exp Med       Date:  1961-02-01       Impact factor: 14.307

10.  FIBRINOGEN PRECIPITATION BY STREPTOCOCCAL M PROTEIN. I. IDENTITY OF THE REACTANTS, AND STOICHIOMETRY OF THE REACTION.

Authors:  F S KANTOR
Journal:  J Exp Med       Date:  1965-05-01       Impact factor: 14.307

View more
  15 in total

1.  Expression of M type 12 protein by a group A streptococcus exhibits phaselike variation: evidence for coregulation of colony opacity determinants and M protein.

Authors:  W J Simpson; P P Cleary
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

Review 2.  Streptococcal M protein: molecular design and biological behavior.

Authors:  V A Fischetti
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

3.  Streptococcin A-FF22: nisin-like antibiotic substance produced by a group A streptococcus.

Authors:  J R Tagg; L W Wannamaker
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

4.  Molecular evolution of streptococcal M protein: cloning and nucleotide sequence of the type 24 M protein gene and relation to other genes of Streptococcus pyogenes.

Authors:  A R Mouw; E H Beachey; V Burdett
Journal:  J Bacteriol       Date:  1988-02       Impact factor: 3.490

5.  Genetic separation of serum opacity factor from M protein of group A streptococci.

Authors:  P P Cleary
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

6.  Possible dual function of M protein: resistance to bacteriophage A25 and resistance to phagocytosis by human leukocytes.

Authors:  P P Cleary; Z Johnson
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

7.  Bacteriophage control of antiphagocytic determinants in group A streptococci.

Authors:  J G Spanier; P P Cleary
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

8.  Coregulation of type 12 M protein and streptococcal C5a peptidase genes in group A streptococci: evidence for a virulence regulon controlled by the virR locus.

Authors:  W J Simpson; D LaPenta; C Chen; P P Cleary
Journal:  J Bacteriol       Date:  1990-02       Impact factor: 3.490

9.  Transformation of Streptococcus sanguis Challis by plasmid deoxyribonucleic acid from Streptococcus faecalis.

Authors:  D J LeBlanc; F P Hassell
Journal:  J Bacteriol       Date:  1976-10       Impact factor: 3.490

10.  Genetic basis of streptococcin A-FF22 production.

Authors:  J R Tagg; L W Wannamaker
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.